Aligos Therapeutics Inc
$ 9.65
-4.55%
29 Dec - close price
- Market Cap 62,213,000 USD
- Current Price $ 9.65
- High / Low $ 10.01 / 9.33
- Stock P/E N/A
- Book Value 11.67
- EPS -13.54
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.42 %
- 52 Week High 46.80
- 52 Week Low 3.76
About
Aligos Therapeutics, Inc. (ALGS) is an innovative clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in the development of groundbreaking therapies for viral infections and liver diseases. With a robust pipeline targeting chronic hepatitis B and liver fibrosis, Aligos is dedicated to addressing significant unmet medical needs through cutting-edge scientific research and strategic partnerships. The company's commitment to advancing transformative healthcare solutions, combined with its strong focus on high-impact therapeutic areas, makes it an attractive investment prospect for institutional investors seeking growth opportunities in the biopharmaceutical landscape.
Analyst Target Price
$80.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-09 |
| Reported EPS | -3.04 | -1.53 | -2.1133 | -13.1 | -3.07 | 0.03 | -0.22 | -0.22 | -0.41 | -0.43 | -0.53 | -0.51 |
| Estimated EPS | -0.25 | -0.24 | -3.1533 | -3.67 | -2.16 | -0.16 | -0.19 | -0.27 | -0.47 | -0.49 | -0.48 | -0.47 |
| Surprise | -2.79 | -1.29 | 1.04 | -9.43 | -0.91 | 0.19 | -0.03 | 0.05 | 0.06 | 0.06 | -0.05 | -0.04 |
| Surprise Percentage | -1116% | -537.5% | 32.9813% | -256.9482% | -42.1296% | 118.75% | -15.7895% | 18.5185% | 12.766% | 12.2449% | -10.4167% | -8.5106% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALGS
2025-12-26 12:09:30
Aligos Therapeutics has secured $105 million through a private placement deal. This financial infusion is expected to bolster the company's research and development efforts and advance its pipeline of therapeutic candidates. The private placement indicates investor confidence in Aligos Therapeutics' future prospects and its drug development programs.
2025-12-18 13:09:19
This article details significant pre-market stock movements for biotech companies on Thursday, highlighting both gainers and losers. Aligos Therapeutics Inc. (ALGS) and PDS Biotechnology Corp. (PDSB) were among the top pre-market gainers, while Processa Pharmaceuticals Inc. (PCSA) experienced a notable pre-market decline. The report provides a snapshot of potential trading opportunities based on early market sentiment.
2025-12-12 19:09:10
Aligos Therapeutics announced inducement grants of non-qualified stock options to purchase 14,100 shares of its stock for newly hired employees on December 9, 2025. These grants were made under Aligos’ 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement for individuals to join the company. The shares will vest over a four-year period, with 25% vesting after the first year and the remainder in equal monthly installments, contingent on continued employment.
2025-12-12 13:09:47
Aligos Therapeutics announced inducement grants of non-qualified stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4) on December 9, 2025. These grants, totaling 14,100 shares, are reserved for new employees and will vest over a four-year period. The company aims to improve patient outcomes through best-in-class therapies for liver and viral diseases.
2025-12-12 13:09:47
Aligos Therapeutics, Inc. announced that its Compensation Committee granted non-qualified stock options to purchase 14,100 shares to newly hired employees on December 9, 2025. These Inducement Grants were made under Aligos’ 2024 Inducement Plan, exclusively for new hires, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants typically vest over four years, with a portion on the first anniversary and the remainder in equal monthly installments, subject to continued employment.
2025-12-12 13:09:47
Aligos Therapeutics (ALGS) has issued non-qualified stock options for 14,100 shares to new employees under its 2024 Inducement Plan to incentivize them to join the firm. Operating in biotechnology, the company focuses on viral and liver diseases, but faces significant financial challenges, including negative revenue growth and operating margins, resulting in a distressed Altman Z-Score. Despite these issues and high stock volatility, its Beneish M-Score suggests no financial statement manipulation and it maintains comfortable interest coverage.
